PL EN


Preferences help
enabled [disable] Abstract
Number of results
2007 | 55 | 6 | 399-403
Article title

Immunomodulation by alpha(1)-proteinase inhibitor: lack of chemotactic effects of recombinant human alpha(1)-proteinase inhibitor from yeast on human peripheral blood granulocytes

Content
Title variants
Languages of publication
EN
Abstracts
EN
Introduction: Recombinant alpha(1)-proteinase inhibitor, clinically developed for inhalative augmentation therapy in patients with alpha(1)-proteinase inhibitor deficiency or cystic fibrosis, may directly contribute to leukocyte accumulation as it may function as a chemoattractant. The migratory effects of yeast-derived human recombinant alpha(1)-proteinase inhibitor on human peripheral blood neutrophils and eosinophils were therefore tested in vitro. Materials and Methods: Human peripheral blood leukocytes were prepared from forearm venous blood and tested for migration toward various preparations of yeast-derived recombinant alpha(1)-proteinase inhibitor in modified Boyden-chamber micropore filter assays. Results: No direct effects of yeast-derived recombinant human alpha(1)-proteinase inhibitor on in vitro migration of isolated neutrophils or eosinophils were seen. Conclusions: The lack of direct chemotactic effects of recombinant human alpha(1)-proteinase inhibitor despite anti-inflammatory effects in other biological activities of leukocytes may contribute to the preserved antibacterial defense mechanisms observed in patients under experimental augmentation therapy with inhaled alpha(1)-proteinase inhibitor.
References
Document Type
ARTICLE
Publication order reference
Christian J. Wiedermann, Department of Medicine, Central Hospital of Bolzano, L. Bohler Street 5, 39100 Bolzano (BZ), Italy
YADDA identifier
bwmeta1.element.element-from-psjc-b6cfb89d-ab50-3903-ae25-e7d2579c4406
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.